* Indications:
Hepatic Encephalopathy:
IDIBACT 550 mg is indicated for reduction in the risk of recurrence of overt hepatic encephalopathy (HE) in patients (>/= 18 years of age) with advanced liver disease.
Differences in treatment effect in patients using lactulose concomitantly with rifaximin couldn’t be assessed.
There is increased systemic exposure in patients with more severe hepatic dysfunction.
IDIBACT 550 MG 20 TAB
103.75 EGP
متوفر في المخزون
الوزن | 100 kg |
---|
RIFAXIMIN 550 MG - indicated for reduction in the risk of recurrence of overt Hepatic Encephalopathy (HE) in patients (>/= 18 years of age) with advanced liver disease